CRISPR Therapeutics AGCRSP決算レポート
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. I...
CRSP Q4 2025 Key Financial Metrics
売上高
$864.0K
粗利益
N/A
営業利益
$-154.8M
純利益
$-130.6M
粗利益率
N/A
営業利益率
-17912.5%
純利益率
-15117.2%
前年比成長
-97.6%
EPS
$-1.32
資金フロー
CRISPR Therapeutics AG Q4 2025 財務サマリー
CRISPR Therapeutics AG reported revenue of $864.0K (down 97.6% YoY) for Q4 2025, with a net profit of $-130.6M (down 250.1% YoY) (-15117.2% margin). Cost of goods sold was N/A.
主要財務指標
| 総売上高 | $864.0K |
|---|---|
| 純利益 | $-130.6M |
| 粗利益率 | N/A |
| 営業利益率 | -17912.5% |
| 報告期間 | Q4 2025 |
CRISPR Therapeutics AG 年度売上推移
CRISPR Therapeutics AG annual revenue history includes year-by-year totals (for example, 2025 revenue was $3.5M). Click any linked year to see what changed vs the prior 10-K.
CRISPR Therapeutics AG 四半期売上・純利益の履歴
CRISPR Therapeutics AG quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| 四半期 | 売上高 | 売上前年比 | 純利益 | 純利益率 |
|---|---|---|---|---|
| Q4 2025 | $864.0K | -97.6% | $-130.6M | -15117.2% |
| Q3 2025 | $889.0K | +47.7% | $-106.4M | -11973.1% |
| Q2 2025 | $892.0K | +72.5% | $-208.5M | -23379.9% |
| Q1 2025 | $865.0K | +71.6% | $-136.0M | -15722.1% |
| Q4 2024 | $35.7M | -82.3% | $-37.3M | -104.5% |
| Q3 2024 | $602.0K | — | $-85.9M | -14276.1% |
| Q2 2024 | $517.0K | -99.3% | $-126.4M | -24450.3% |
| Q1 2024 | $504.0K | -99.5% | $-116.6M | -23133.1% |
損益計算書
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 売上高 | $504000 | $517000 | $602000 | $35.7M | $865000 | $892000 | $889000 | $864000 |
| 前年比成長 | -99.5% | -99.3% | N/A | -82.3% | 71.6% | 72.5% | 47.7% | -97.6% |
貸借対照表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 総資産 | $2.44B | $2.34B | $2.26B | $2.24B | $2.17B | $2.03B | $2.25B | $2.27B |
| 総負債 | $355.1M | $358.9M | $316.5M | $310.0M | $336.9M | $318.6M | $329.3M | $343.4M |
| 株主資本 | $2.08B | $1.98B | $1.94B | $1.93B | $1.83B | $1.71B | $1.92B | $1.92B |
キャッシュフロー
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 営業CF | $109.8M | $-95.6M | $-106.9M | $-50.0M | $-53.9M | $-113.9M | $-84.6M | $-92.6M |